Desmethylflunitrazepam

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Desmethylflunitrazepam produces a classic benzodiazepine experience dominated by heavy sedation, anxiety relief, and physical relaxation, consistent with its role as an active metabolite of flunitrazepam. Little formal documentation of its subjective character exists, as it has circulated primarily as a designer benzodiazepine sold online. Memory of the period following ingestion is often unreliable at moderate to high doses.

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Desmethylflunitrazepam was originally identified as an active metabolite of flunitrazepamcitation needed, the potent benzodiazepine marketed under trade names such as Rohypnol. The compound has since emerged on the grey market as a designer drug, sold online as a research chemical under names including fonazepam and the research designation Ro05-4435.

• 
  Step 1 · Automated synthesis

  An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

• 
  Step 2 · First-pass review

  A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

• Step 3 · Citation reviewPending

  No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Spotted a mistake, an outdated claim, or something missing from the Desmethylflunitrazepam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.